LEAVDO CAPSULES 25 MG

• LENALIDOMIDE25 milligramต่อ 1 capsule

ประเภทควบคุม

ยาควบคุมพิเศษ

ข้อบ่งใช้

Multiple myeloma Leavdo as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Leavdo as combination therapy is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Leavdo in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromes Leavdo as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. Mantle cell lymphoma Leavdo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma

รหัส ATC

L04AX (Other immunosuppressants)

ข้อมูลตามที่ขึ้นทะเบียนกับ อย. — ไม่ใช่คำแนะนำการใช้ยา ปรึกษาเภสัชกรหรือแพทย์ก่อนใช้เสมอ